Regarding “The 50th anniversary of abdominal aortic reconstruction”  by Leeds, Frank H.
These features are relevant to the phenomenon of UH-
induced platelet activation because of the following.
1. UH is used in patients with vascular disease. As Sobel et al1
point out, platelet activation in these patients is undesirable.
The clinical and experimental situations described above pro-
vide an opportunity to assess the clinical relevance of direct
UH-induced platelet activation.
2. The findings described above provide models where the mo-
lecular basis of the mechanism described by Sobel et al1 can
be assessed. For example, it is expected that LMWH will bind
less to Gp IIb/IIIa than UH. Similarly, UH binding and/or
outside-in signaling should be enhanced in patients with
peripheral vascular disease, especially if they demonstrate
platelet hyperactivity.
Direct platelet activation by UH may reduce the benefit
accrued from the use of this anticoagulant. This concept is likely
to be further clarified now that Sobel et al1 have worked out the
process of direct UH-induced platelet activation.
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Regarding “The 50th anniversary of abdominal
aortic reconstruction”
In his historical review of abdominal aortic reconstruction (J
Vasc Surg 2001;33:895-8), Dr Friedman has written a tribute of
Dubost and Oudot with empathy, but, to quote Goethe, “Often
when primacy is claimed, the pleasure of discovery is spoiled
because we are not the first.” Their excellent work1 has been well
recognized, while that of Freeman,2 who preceded them, has
been ignored, except by Bergan.3
Many surgeons, on returning home at the end of World War
II, found conditions ideal for laboratory and clinical research. The
scene was thus set for the explosive development of vascular
surgery during its golden decade (1946-1956). In San Francisco,
at the medical school of the University of California, a small
group (Gilfillan, Wylie, and Leeds) commenced, under the guid-
ance of Dr Freeman, to work on various problems in vascular
surgery. These were wonderful years, filled with the joy of learn-
ing, but we soon found out that there is no easy road to first dis-
coveries. As F. Paiz expresses it, “Traveler, there is no path, the
path is made by walking.”
Dr Freeman asked me to study (1) the possibility of de-
veloping an experimental model of aneurysm and (2) the
bursting pressures of arteries and veins. At that time, in our
operative approach to abdominal aortic aneurysms, we had
tried ligation, wiring, and cellophane wrapping, but the results
and complications were discouraging. As the data on bursting
pressures in the experimental animal suggested that the 
iliac vein would withstand arterial pressures, on February 12,
1951, we resected an aneurysm and replaced it with a vein
graft taken from the patient’s left common iliac vein and 
its bifurcation. Six hours postoperation the patient died. We
were unable to obtain an autopsy, but the sudden death, we
felt, was due to rupture of the vein graft. Therefore, 
on February 26, 1951, when we were presented with a 55-
year-old man with a large symptomatic aneurysm, Freeman
modified the operation by opening the aneurysm longitudi-
nally, and a vein graft, consisting of the patient’s left common
iliac vein and its bifurcation, was sutured within the aneurys-
mal sack to the aorta and iliac arteries. The aneurysmal sack
was then closed around the graft.
The 15-month follow-up, including an aortogram at 4
months, showed an excellent result. This case was presented at
the first meeting of the International Society of Angiology (now
the American Association for Vascular Surgery) on June 9, 1951,
and published in Angiology in December 1951.4
The obvious problem with this technique was the extra time
and trauma needed to obtain the autologous graft. A cadaver
graft seemed the solution, but Freeman, on the basis of earlier
studies,5 refused to consider it, as he felt a homologous graft
would not hold up over time.
Then in June of 1952, Freeman returned from a trip to the
East Coast with the exciting news of Voorhees’ dramatic break-
through6 and a piece of Vinyon-N cloth, given to him by
Blakemore, and aortic aneurysm surgery was really on its way, for
now we had a readily available graft for the inlay technique, which
was used, from then on, by Freeman and myself and was eventu-
ally popularized by Creech.7 Our inlay technique was a simpler
one than the excisional one, later developed by Dubost, which
required “a sometimes difficult and hazardous dissection.”
This explosive development in vascular surgery was not local-
ized, but generalized throughout Europe and America. Should
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we not then say that all who were part of that generation were
part of the First?
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Competition of interest: FHL was associated with Dr Norman E. Freeman
in research, teaching, and private practice of vascular surgery from July
1946 to September 1957.
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Regarding “Preprocedural risk stratification:
Identifying an appropriate population for carotid
stenting”
We read with interest the article by Dr Ouriel and his col-
leagues from The Cleveland Clinic Foundation (J Vasc Surg
2001;33:728-32). There is a recent nationwide explosion of
interest in treating patients at high risk for carotid endarterec-
tomy (CEA) with percutaneous angioplasty and stenting (CAS).
Similar to the conclusion arrived at by Ouriel et al, we randomly
assigned patients with significant baseline comorbid conditions
(cardiac, recurrent stenosis, radiation stenosis, and contralateral
occlusion) to CEA or CAS.
Significant numbers in both treatment groups had grade 3
(SVS/AAVS) cardiac (CAS 72%, CEA 60%; P = .44) and hyper-
tensive (CAS 82%, CEA 80%; P = .65) risk factors. Contralateral
carotid disease (>50% stenosis, occlusion, or prior endarterec-
tomy) was present in 64% of the CAS group and in 60% of the
CEA group. Significantly more reversible cardiac events (hypoten-
sion/bradycardia requiring ≥24 hours of pharmacological sup-
port) were observed in the CAS group (CAS 73%, CEA 20%; P =
.03). Major adverse in-hospital events were noted in one patient in
each group (CAS, myocardial infarction; CEA, death). Local com-
plications were observed in one from each treatment group (CAS
groin hematoma; CEA, recurrent laryngeal nerve paralysis). The
duration of postoperative stay did not reach statistical significance
(CAS, 2.1 ± 1.4 days; CEA, 1.8 ± 1.1 days). However, four
patients in the CAS treatment group were readmitted within 1
month (congestive heart failure, 1; myocardial infarction, 1; rest
pain, 1), compared with no new events in the CEA group.
A disturbing number of patients in the CAS treatment group
experienced profound and prolonged hypotension and bradycar-
dia induced by forced dilatation of the carotid sinus. These phys-
iological changes were not well tolerated by patients with
underlying cardiac risk factors. Based on the findings of our study
population, a treatment algorithm is currently used before ran-
domization (Fig 1). Routine cardiac stress evaluation and coro-
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nary revascularization if possible significantly reduced the adverse
cardiac events noted following CAS. Patients with uncorrectable
cardiac disease are currently not offered CAS at our institution.
Our findings are similar to a study by Gil-Peralta et al1 who
also reported a high incidence of cardiovascular effects: hypoten-
sion (54.1%), bradycardia (67.1%), and asystole in 25.9% of
treated patients. Accurate stent sizing using an intravascular ultra-
sound to measure the normal caliber of the distal internal carotid
artery (ICA), combined with isolated ICA stent placement 
(Fig 2) has also decreased the incidence of post-CAS bradycardia
and hypotension. Evolving technology, such as the development
Fig 1. Treatment algorithm used before randomization.
Fig 2. Isolated stenting of the ICA.
